Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 18, 2023

BUY
$6.7 - $24.21 $323,770 - $1.17 Million
48,324 Added 18.82%
305,059 $7.35 Million
Q1 2023

May 11, 2023

BUY
$6.7 - $24.21 $1.46 Million - $5.26 Million
217,431 Added 553.2%
256,735 $6.19 Million
Q4 2022

Feb 13, 2023

BUY
$4.52 - $10.57 $8,497 - $19,871
1,880 Added 5.02%
39,304 $416,000
Q3 2022

Nov 14, 2022

BUY
$3.43 - $5.62 $15,688 - $25,705
4,574 Added 13.92%
37,424 $168,000
Q2 2022

Aug 11, 2022

SELL
$3.65 - $7.3 $7,332 - $14,665
-2,009 Reduced 5.76%
32,850 $132,000
Q1 2022

May 11, 2022

BUY
$3.4 - $7.88 $21,352 - $49,486
6,280 Added 21.97%
34,859 $255,000
Q4 2021

Feb 10, 2022

BUY
$5.59 - $7.39 $11,789 - $15,585
2,109 Added 7.97%
28,579 $160,000
Q3 2021

Nov 12, 2021

BUY
$5.66 - $8.33 $149,820 - $220,495
26,470 New
26,470 $169,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.